Biopharmaceutical company, Erytech Pharma, was established in Lyon in 2004; its production centre is located in Lyon-Gerland. Erytech Pharma develops innovative therapies in oncology and, in particular, for acute leukaemia and solid tumours.

While awaiting the commercialisation of its first treatment (likely in 2016), Erytech Pharma has raised 30 million euros (with 68% subscribed by American investors) to strengthen and accelerate its presence in the United States (the company is already present in Philadelphia and Boston) and to develop its ongoing studies.

Erytech Pharma also develops innovative tumour-starvation treatment for acute leukaemia and other oncology indications such as pancreatic cancer. This treatment is currently completing Phase III clinical development in Acute Lymphoblastic Leukemia in Europe and is in Phase IIb in Acute Myeloid Leukemia. Its commercialisation will be enabled by two distribution partnership agreements with Orphan Europe (Recordati Group), and the other in Israel with the TEVA Group.